A corporate venture capital arm of a global pharmaceutical company with a long operating history and an international footprint is actively seeking new investments. The parent organization operates worldwide and has expanded its global reach through strategic acquisitions in recent years. As part of its broader open innovation strategy, the parent organization actively pursues in- and out-licensing, early-stage partnerships, and strategic investments. The firm is responsible for executing strategic investments that support future partnering opportunities and help build the parent organization’s therapeutic pipeline.
The firm was established a few years ago and operates from the United States. The firm manages an evergreen fund and focuses on pre-clinical startups with differentiated platforms and first-in-class programs in human therapeutics. The firm participates in Seed and Series A financing rounds, typically investing up to USD $5M initially, with the ability to invest up to USD $10M per company through follow-on capital. The firm is open to engaging with companies globally and has built a portfolio of more than a dozen investments, primarily across Europe and the United States.
The firm targets pre-clinical to pre-IND, in-human therapeutics companies. Key areas of interest include oncology, neurology, immunology, and specialty disease areas such as fibrosis, endocrine disorders, and rare genetic diseases. The firm is modality-agnostic and considers small molecules, antibodies, nucleic acid-based therapies, and gene therapies. The firm does not invest in medical devices or diagnostics.
The firm does not lead financing rounds. When co-investing or participating in syndicated rounds, the firm requires a board observer seat.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 